Davies G, Hamilton S, Hendrickson E, Levy R, Post F
Age Ageing. 1977 Aug;6(3):156-62. doi: 10.1093/ageing/6.3.156.
In a double-blind clinical trial the effects of the vasodilator drug cyclandelate (in a dose of 1200 mg daily) were studied in a group of patients with depressive illnesses or dementing conditions. The measures used before treatment and after six weeks' treatment were: clinical rating, psychometric tests (Paired Associate Learning Test, Digit Copying Test, Digit Substitution Test, and Serial Learning Test), cortical evoked potentials, the sedation threshold and the Gresham Questionnaire. In the depressive group there were no significant differences in the changes in scores at six weeks in three groups: those who received cyclandelate plus amitriptyline, those who received placebo plus amitriptyline, and those who received neither placebo nor cyclandelate. In the demented group there were significant changes in favour of the placebo on two measures (Digit Copying test, and one component of the auditory evoked response). The results do not support the previously reported views claiming, in a number of studies, a significant improvement in the performance of both demented and normal elderly subjects treated with cyclandelate. The significance of these findings is discussed.
在一项双盲临床试验中，研究了血管扩张剂环扁桃酯（每日剂量1200毫克）对一组患有抑郁症或痴呆症的患者的疗效。治疗前和治疗六周后的测量指标包括：临床评分、心理测试（配对联想学习测试、数字抄写测试、数字替代测试和系列学习测试）、皮层诱发电位、镇静阈值和格雷沙姆问卷。在抑郁症组中，接受环扁桃酯加阿米替林的患者、接受安慰剂加阿米替林的患者以及既未接受安慰剂也未接受环扁桃酯的患者这三组在六周时的得分变化没有显著差异。在痴呆组中，在两项测量指标（数字抄写测试和听觉诱发电位的一个成分）上，安慰剂组有显著改善。这些结果不支持先前一些研究中所声称的观点，即环扁桃酯治疗可使痴呆和正常老年受试者的表现有显著改善。讨论了这些发现的意义。
